openPR Logo
Press release

Eosinophilic Esophagitis Drug Market Detail Analysis focusing on Application, Types and Regional Outlook 2026| AstraZeneca, GSK, Bayer

02-10-2020 10:28 AM CET | Health & Medicine

Press release from: QY Research, INC.

Eosinophilic Esophagitis Drug Market Detail Analysis focusing

QY Research offers its latest report on the Global Eosinophilic Esophagitis Drug Market Size, Status and Forecast 2020-2026 that includes comprehensive analysis on a range of subjects such as competition, segmentation, regional expansion, and market dynamics.

Some of the Major key players operating in this Report are: AstraZeneca, GSK, Bayer, Adare Pharmaceuticals, DBV Technologies, Dr. Falk Pharma, Quorum Innovations, Takeda, Calypso, Celgene, Regeneron

The report has covered exhaustive assessment of the current scenario and future progress of the Global Eosinophilic Esophagitis Drug industry. Additionally, it has touched upon aspects such as drivers, challenges, opportunities, trends, and developments pertaining to the global Eosinophilic Esophagitis Drug production. These projections have been obtained from research methodologies such as PESTLE analysis, SWOT analysis, and PORTER's Five Forces.

The report focuses on the micro- and macro-economic factors that are anticipated to impact the growth of the industry positively. The report has also shed light on Eosinophilic Esophagitis Drug sales, production, demand, consumption, and gross margin. Moreover, challenges and limitations that the business is likely to face in the forthcoming years are mapped in the report.

Latest Sample Copy of this Eosinophilic Esophagitis Drug Market Report(Including Full Table of Content, List of Tables & Figures, Chart)@ https://www.qyresearch.com/sample-form/form/1504223/global-eosinophilic-esophagitis-drug-industry-research-report-growth-trends-and-competitive-analysis-2020-2026

To understand the structure, the report has segregated the global Eosinophilic Esophagitis Drug Market into segments comprising product type, vertical, and application.  The study is done based on CAGR, share, size, production, and consumption. Besides, the report has offered region-wise analysis, wherein prospective regions and respective countries are studied. This information will act as an effective tool for the global Eosinophilic Esophagitis Drug players to recognize the promising areas and make effective investments in the coming future.

This report includes the following Leading Players & we can also add the other companies as you want:

AstraZeneca, GSK, Bayer, Adare Pharmaceuticals, DBV Technologies, Dr. Falk Pharma, Quorum Innovations, Takeda, Calypso, Celgene, Regeneron

Market Segment by Type

Budesonide, Fluticasone, OthersMarket

Market Segment by Application

Hospitals, Clinics, Drugstore

Get Customized Report in your Inbox within 24 hours: https://www.qyresearch.com/customize-request/form/1504223/global-eosinophilic-esophagitis-drug-industry-research-report-growth-trends-and-competitive-analysis-2020-2026

Table of Contents

1 Report Overview
1.1 Research Scope
1.2 Top Eosinophilic Esophagitis Drug Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Eosinophilic Esophagitis Drug Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Budesonide
1.3.3 Fluticasone
1.3.4 Others
1.4 Market Segment by Application
1.4.1 Global Eosinophilic Esophagitis Drug Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Drugstore
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Eosinophilic Esophagitis Drug Revenue (2015-2026)
2.1.1 Global Eosinophilic Esophagitis Drug Revenue (2015-2026)
2.1.2 Global Eosinophilic Esophagitis Drug Sales (2015-2026)
2.2 Eosinophilic Esophagitis Drug Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Eosinophilic Esophagitis Drug Sales by Regions (2015-2020)
2.2.2 Global Eosinophilic Esophagitis Drug Revenue by Regions (2015-2020)
2.3 Global Top Eosinophilic Esophagitis Drug Regions (Countries) Ranking by Market Size
2.4 Eosinophilic Esophagitis Drug Industry Trends
2.4.1 Eosinophilic Esophagitis Drug Market Top Trends
2.4.2 Market Drivers
2.4.3 Eosinophilic Esophagitis Drug Market Challenges
2.4.4 Porter's Five Forces Analysis
2.4.5 Primary Interviews with Key Eosinophilic Esophagitis Drug Players: Views for Future

3 Competitive Landscape by Manufacturers
3.1 Global Top Eosinophilic Esophagitis Drug Manufacturers by Sales (2015-2020)
3.1.1 Global Eosinophilic Esophagitis Drug Sales by Manufacturers (2015-2020)
3.1.2 Global Eosinophilic Esophagitis Drug Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Eosinophilic Esophagitis Drug Sales in 2019
3.2 Global Top Manufacturers Eosinophilic Esophagitis Drug by Revenue
3.2.1 Global Eosinophilic Esophagitis Drug Revenue by Manufacturers (2015-2020)
3.2.2 Global Eosinophilic Esophagitis Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Eosinophilic Esophagitis Drug Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Eosinophilic Esophagitis Drug as of 2019)
3.4 Global Eosinophilic Esophagitis Drug Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Eosinophilic Esophagitis Drug Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Eosinophilic Esophagitis Drug Market
3.7 Key Manufacturers Eosinophilic Esophagitis Drug Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Eosinophilic Esophagitis Drug Historic Market Review by Type (2015-2020)
4.1.2 Global Eosinophilic Esophagitis Drug Sales Market Share by Type (2015-2020)
4.1.3 Global Eosinophilic Esophagitis Drug Revenue Market Share by Type (2015-2020)
4.1.4 Eosinophilic Esophagitis Drug Price by Type (2015-2020)
4.1 Global Eosinophilic Esophagitis Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Eosinophilic Esophagitis Drug Sales Forecast by Type (2021-2026)
4.2.3 Global Eosinophilic Esophagitis Drug Revenue Forecast by Type (2021-2026)
4.2.4 Eosinophilic Esophagitis Drug Price Forecast by Type (2021-2026)

5 Global Eosinophilic Esophagitis Drug Market Size by Application
5.1 Global Eosinophilic Esophagitis Drug Historic Market Review by Application (2015-2020)
5.1.2 Global Eosinophilic Esophagitis Drug Sales Market Share by Application (2015-2020)
5.1.3 Global Eosinophilic Esophagitis Drug Revenue Market Share by Application (2015-2020)
5.1.4 Eosinophilic Esophagitis Drug Price by Application (2015-2020)
5.2 Global Eosinophilic Esophagitis Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Eosinophilic Esophagitis Drug Sales Forecast by Application (2021-2026)
5.2.3 Global Eosinophilic Esophagitis Drug Revenue Forecast by Application (2021-2026)
5.2.4 Eosinophilic Esophagitis Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Eosinophilic Esophagitis Drug Breakdown Data by Company
6.2 North America Eosinophilic Esophagitis Drug Breakdown Data by Type
6.3 North America Eosinophilic Esophagitis Drug Breakdown Data by Application
6.4 North America Eosinophilic Esophagitis Drug Breakdown Data by Countries
6.4.1 North America Eosinophilic Esophagitis Drug Sales by Countries
6.4.2 North America Eosinophilic Esophagitis Drug Revenue by Countries
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Eosinophilic Esophagitis Drug Breakdown Data by Company
7.2 Europe Eosinophilic Esophagitis Drug Breakdown Data by Type
7.3 Europe Eosinophilic Esophagitis Drug Breakdown Data by Application
7.4 Europe Eosinophilic Esophagitis Drug Breakdown Data by Countries
7.4.1 Europe Eosinophilic Esophagitis Drug Sales by Countries
7.4.2 Europe Eosinophilic Esophagitis Drug Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Eosinophilic Esophagitis Drug Breakdown Data by Company
8.2 Asia Pacific Eosinophilic Esophagitis Drug Breakdown Data by Type
8.3 Asia Pacific Eosinophilic Esophagitis Drug Breakdown Data by Application
8.4 Asia Pacific Eosinophilic Esophagitis Drug Breakdown Data by Regions
8.4.1 Asia Pacific Eosinophilic Esophagitis Drug Sales by Regions
8.4.2 Asia Pacific Eosinophilic Esophagitis Drug Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Eosinophilic Esophagitis Drug Breakdown Data by Company
9.2 Latin America Eosinophilic Esophagitis Drug Breakdown Data by Type
9.3 Latin America Eosinophilic Esophagitis Drug Breakdown Data by Application
9.4 Latin America Eosinophilic Esophagitis Drug Breakdown Data by Countries
9.4.1 Latin America Eosinophilic Esophagitis Drug Sales by Countries
9.4.2 Latin America Eosinophilic Esophagitis Drug Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Eosinophilic Esophagitis Drug Breakdown Data by Type
10.2 Middle East and Africa Eosinophilic Esophagitis Drug Breakdown Data by Application
10.3 Middle East and Africa Eosinophilic Esophagitis Drug Breakdown Data by Countries
10.3.1 Middle East and Africa Eosinophilic Esophagitis Drug Sales by Countries
10.3.2 Middle East and Africa Eosinophilic Esophagitis Drug Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E

11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Business Overview and Total Revenue (2019 VS 2018)
11.1.3 AstraZeneca Eosinophilic Esophagitis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 AstraZeneca Eosinophilic Esophagitis Drug Products and Services
11.1.5 AstraZeneca SWOT Analysis
11.1.6 AstraZeneca Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Business Overview and Total Revenue (2019 VS 2018)
11.2.3 GSK Eosinophilic Esophagitis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 GSK Eosinophilic Esophagitis Drug Products and Services
11.2.5 GSK SWOT Analysis
11.2.6 GSK Recent Developments
11.3 Bayer
11.3.1 Bayer Corporation Information
11.3.2 Bayer Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Bayer Eosinophilic Esophagitis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Bayer Eosinophilic Esophagitis Drug Products and Services
11.3.5 Bayer SWOT Analysis
11.3.6 Bayer Recent Developments
11.4 Adare Pharmaceuticals
11.4.1 Adare Pharmaceuticals Corporation Information
11.4.2 Adare Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Products and Services
11.4.5 Adare Pharmaceuticals SWOT Analysis
11.4.6 Adare Pharmaceuticals Recent Developments
11.5 DBV Technologies
11.5.1 DBV Technologies Corporation Information
11.5.2 DBV Technologies Business Overview and Total Revenue (2019 VS 2018)
11.5.3 DBV Technologies Eosinophilic Esophagitis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 DBV Technologies Eosinophilic Esophagitis Drug Products and Services
11.5.5 DBV Technologies SWOT Analysis
11.5.6 DBV Technologies Recent Developments
11.6 Dr. Falk Pharma
11.6.1 Dr. Falk Pharma Corporation Information
11.6.2 Dr. Falk Pharma Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Dr. Falk Pharma Eosinophilic Esophagitis Drug Products and Services
11.6.5 Dr. Falk Pharma SWOT Analysis
11.6.6 Dr. Falk Pharma Recent Developments
11.7 Quorum Innovations
11.7.1 Quorum Innovations Corporation Information
11.7.2 Quorum Innovations Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Quorum Innovations Eosinophilic Esophagitis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Quorum Innovations Eosinophilic Esophagitis Drug Products and Services
11.7.5 Quorum Innovations SWOT Analysis
11.7.6 Quorum Innovations Recent Developments
11.8 Takeda
11.8.1 Takeda Corporation Information
11.8.2 Takeda Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Takeda Eosinophilic Esophagitis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Takeda Eosinophilic Esophagitis Drug Products and Services
11.8.5 Takeda SWOT Analysis
11.8.6 Takeda Recent Developments
11.9 Calypso
11.9.1 Calypso Corporation Information
11.9.2 Calypso Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Calypso Eosinophilic Esophagitis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Calypso Eosinophilic Esophagitis Drug Products and Services
11.9.5 Calypso SWOT Analysis
11.9.6 Calypso Recent Developments
11.10 Celgene
11.10.1 Celgene Corporation Information
11.10.2 Celgene Business Overview and Total Revenue (2019 VS 2018)
11.10.3 Celgene Eosinophilic Esophagitis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 Celgene Eosinophilic Esophagitis Drug Products and Services
11.10.5 Celgene SWOT Analysis
11.10.6 Celgene Recent Developments
11.11 Regeneron
11.11.1 Regeneron Corporation Information
11.11.2 Regeneron Business Overview and Total Revenue (2019 VS 2018)
11.11.3 Regeneron Eosinophilic Esophagitis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.11.4 Regeneron Eosinophilic Esophagitis Drug Products and Services
11.11.5 Regeneron SWOT Analysis
11.11.6 Regeneron Recent Developments

12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Eosinophilic Esophagitis Drug Sales Channels
12.2.2 Eosinophilic Esophagitis Drug Distributors
12.3 Eosinophilic Esophagitis Drug Customers

13 Estimates and Projections by Regions (2021-2026)
13.1 Global Eosinophilic Esophagitis Drug Sales Forecast (2021-2026)
13.1.1 Global Eosinophilic Esophagitis Drug Sales Forecast by Regions (2021-2026)
13.1.2 Global Eosinophilic Esophagitis Drug Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Eosinophilic Esophagitis Drug Sales Forecast (2021-2026)
13.2.2 North America Eosinophilic Esophagitis Drug Revenue Forecast (2021-2026)
13.2.3 North America Eosinophilic Esophagitis Drug Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Eosinophilic Esophagitis Drug Sales Forecast (2021-2026)
13.3.2 Europe Eosinophilic Esophagitis Drug Revenue Forecast (2021-2026)
13.3.3 Europe Eosinophilic Esophagitis Drug Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Eosinophilic Esophagitis Drug Sales Forecast (2021-2026)
13.4.2 Asia Pacific Eosinophilic Esophagitis Drug Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Eosinophilic Esophagitis Drug Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Eosinophilic Esophagitis Drug Sales Forecast (2021-2026)
13.5.2 Latin America Eosinophilic Esophagitis Drug Revenue Forecast (2021-2026)
13.5.3 Latin America Eosinophilic Esophagitis Drug Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Eosinophilic Esophagitis Drug Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Eosinophilic Esophagitis Drug Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Eosinophilic Esophagitis Drug Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

Contact US:
QY Research, INC.
17890 Castleton, Suite 218,
Los Angeles, CA - 91748
USA: +1 626 428 8800
India: +91 9766 478 224
Emails - enquiry@qyresearch.com
Web - www.qyresearch.com

ABOUT US:
QY Research is a leading global market research and consulting company. Established in 2007 in Beijing, China, QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and custom research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Eosinophilic Esophagitis Drug Market Detail Analysis focusing on Application, Types and Regional Outlook 2026| AstraZeneca, GSK, Bayer here

News-ID: 1924980 • Views: 397

More Releases from QY Research, INC.

Tension Free Vaginal Tape (TVT) Market Growth Factor with Regional Forecast, Mar …
LOS ANGELES, United States: QY Research offers an encyclopedic study of the global Tension Free Vaginal Tape (TVT) market with holistic insights into vital factors and aspects that impact future market growth. The global Tension Free Vaginal Tape (TVT) market has been analyzed for the forecast period 2022-2028 and historical period 2017-2021. In order to help players to gain comprehensive understanding of the global Tension Free Vaginal Tape (TVT) market…
Minimally Invasive Urinary Incontinence Device Market Recent Trends, Opportuniti …
LOS ANGELES, United States: QY Research offers an encyclopedic study of the global Minimally Invasive Urinary Incontinence Device market with holistic insights into vital factors and aspects that impact future market growth. The global Minimally Invasive Urinary Incontinence Device market has been analyzed for the forecast period 2022-2028 and historical period 2017-2021. In order to help players to gain comprehensive understanding of the global Minimally Invasive Urinary Incontinence Device market…
Female Urinary Incontinence Treatment Device Market 2022: Key Market Insights, D …
LOS ANGELES, United States: QY Research offers an encyclopedic study of the global Female Urinary Incontinence Treatment Device market with holistic insights into vital factors and aspects that impact future market growth. The global Female Urinary Incontinence Treatment Device market has been analyzed for the forecast period 2022-2028 and historical period 2017-2021. In order to help players to gain comprehensive understanding of the global Female Urinary Incontinence Treatment Device market…
Urinary Incontinence Electrical Stimulation Device Market Regional Analysis, key …
LOS ANGELES, United States: QY Research offers an encyclopedic study of the global Urinary Incontinence Electrical Stimulation Device market with holistic insights into vital factors and aspects that impact future market growth. The global Urinary Incontinence Electrical Stimulation Device market has been analyzed for the forecast period 2022-2028 and historical period 2017-2021. In order to help players to gain comprehensive understanding of the global Urinary Incontinence Electrical Stimulation Device market…

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or…
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential…
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase…
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals …
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning…